I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site

Oncology

Our understanding of the molecular mechanisms of tumour development and how tumours spread has continually improved, leading to major breakthroughs that have transformed several aspects of cancer care. Roche’s scientists are pioneers in cancer research, and they continuously investigate innovative and personalised treatment options.

Explore the latest in Roche's research and developments in oncology.

Preview the latest medical materials

Sign up or login to unlock the full suite of MEDICALLY features

Nov 19 / Roche
Genomics Annotation and Interpretation in Somatic Oncology with a Highly Structured Data Model
navify® Mutation Profiler provides an automated cloud-based solution to streamline the process of annotating, interpreting and reporting variants from next-generation sequencing (NGS) somatic oncology test results. Ephesus is an internal web application enabling expert curation for construction of a robust knowledgebase of NGS biomarkers to support the mutation profiler. In this study, we assessed the reporting capability of Ephesus/navify Mutation profiler by querying somatic variants in ~170K real cancer cases from the AACR GENIE® (v16.1) project, and comparing against several public knowledgebases. Ephesus/navify Mutation Profiler outperformed the other knowledgebases in having the highest number of interpreted cases and biomarker profiles.

Sign up or login to unlock the full suite of MEDICALLY features

Nov 19 / Roche and Genentech
Cost-Effectiveness Analysis (CEA) of Pertuzumab and Trastuzumab (PH) + Chemotherapy (CT) Versus H + CT in HER2-Positive Early Breast Cancer (EBC): Updated Model Using Data from the 8.4-Year Follow-Up of APHINITY
The randomised, global, Phase III APHINITY trial assessed the addition of pertuzumab to trastuzumab and chemotherapy for the adjuvant treatment of HER2-positive early breast cancer. A previous cost-effectiveness analysis model used primary analysis data from APHINITY to project cost-effectiveness of pertuzumab plus trastuzumab-based therapy in the US; the current poster reports an updated cost-effectiveness analysis model with data from the third interim analysis of APHINITY in three countries (Belgium, Spain and the Republic of Ireland), along with an exploration of how changes in the metastatic breast cancer treatment landscape can impact the results of the early breast cancer model.

Sign up or login to unlock the full suite of MEDICALLY features

Personalised Healthcare
Nov 19 / Roche
Timing of Next-Generation Sequencing (NGS) Relative to First-Line Therapy in Lung Cancer: Insights from the Global WAYFIND-R Registry
WAYFIND-R is a global, multicentre, prospective pan-cancer registry collecting long-term data from patients diagnosed with a solid tumour profiled with next-generation sequencing (NGS). The poster presents insights about the timing of NGS relative to first-line therapy in lung cancer.
Upcoming congresses
Access to Roche and Genentech’s latest medical information
View related congresses

Ask a question or share feedback